Banner NPRA

               
Product Search   QUEST3+ System   Enquiries   Sitemap  

Announcement to Product Registration Holders (PRHs): Pilot Project for Post-Approval Changes (Variation) Using Reliance

Bintang tidak aktifBintang tidak aktifBintang tidak aktifBintang tidak aktifBintang tidak aktif
 

NPRA has been conducting a pilot project to explore the use of reliance for post-approval changes (variation). This initiative is on-going and is expected to conclude by 1 June 2025.

This pilot will help us assess the effectiveness of utilising reliance approach for post-approval changes, aiming to reduce timelines and improve efficiency.

Requirements for this pilot are as follows:

  1. A Letter of Intent (LOI)/ cover letter to use reliance for the application.
  2. Official approval letter or notification of the post-approval changes from chosen reference agency/ WHO.
  3. Assessment report from chosen reference agency. In particular, if details of the approved changes are not included in the approval letter, the assessment report will be required. For biologic products, the assessment report is required at the time of submission.
  4. Q&A documentation will be requested during evaluation if required.
  5. An overall summary of changes. A comparative tabulated format showing both the approved and proposed changes should be provided, where applicable.

Please ensure that the variations submitted are in accordance with those submitted in the reference agency. The timeline for this reliance pathway will be as follows:

Type of variation groupings Timeline (working day - WD)
Including MaV/MaVB Not more than 100 WD
Excluding MaV/MaVB Not more than 80 WD

It is not advisable to bundle them with other variations that are not part of the reliance submission. The timeline above will not be applicable if the submission includes other variations that are not part of the reliance submission.

Steps for submission:

  1. Submit a variation application through Quest 3+ in accordance with the variation categories outlined in the Malaysian Variation Guideline for Pharmaceutical Products, 2nd Edition (July 2022) or Malaysian Variation Guideline for Biologics (MVGB), 1st edition (Jan 2017).
  2. In your online variation submission, please also add the variation category MiV-N (Post-approval Changes Reliance Pilot Project) to identify the application as a reliance application.
  3. Notify the respective Head of Section via email regarding the reliance application.

 

Applicants are advised to consult the respective Head of Sections if there are any queries.

 

 

National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

  • Phone: +603-7883 5400

 

 

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Site Last Modified

  • Last Modified: Selasa 19 November 2024, 12:04:51.
© Copyright 2018 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA

Search

Menu Utama